IMPACT OF EARLY VIRAL SUPPRESSION ON HIV INCIDENCE ASSAYS: HPTN 071 (POPART)

Wendy Grant-McAuley
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States

Presented at virtual CROI 2021
Background:
• Serologic assays are used for cross-sectional HIV incidence estimation.
• Viral suppression from antiretroviral therapy (ART) can impact the performance of these assays in persons with established HIV infection.

Study Objective:
• To evaluate whether initiation of ART in the first year of infection impacts the performance of serologic HIV incidence assays.

Samples used for analysis:
• Samples were obtained from a community-randomized trial that evaluated the impact of universal testing and treatment on HIV incidence in Zambia and South Africa (HPTN 071 [PopART]).
• 219 plasma samples were obtained from participants infected <1 year (seroconverters).
• 62/219 (28.3%) of the samples had viral loads <400 copies/mL.

Laboratory Methods:
• LAg-Avidity assay
• JHU modified BioRad-Avidity assay
• Assanté HIV-1 Rapid Recency assay
• Qualitative multi-drug assay
Results

- There was no difference in mean LAg-avidity values between groups.

- The mean BioRad-avidity value was higher for seroconverters who were suppressed on ART than for those who were viremic.
• Seroconverters who were suppressed on ART were less likely to have the long-term infected band on the rapid LAg assay than those who were viremic.

• Seroconverters who were suppressed on ART were also more likely to have LAg-Avidity values <1.5 than those who were viremic or were virally suppressed in the absence of ART.
Conclusions

- Persons who were virally suppressed on ART in the first year of infection were more likely to have “recent” results using the LAg-Avidity and Rapid LAg assays.

- In contrast, ART-induced viral suppression in the first year of infection did not significantly impact performance of the BioRad-Avidity assay.

- Persons who were suppressed on ART were more likely to have lower LAg-Avidity values than persons who were virally suppressed in the absence of ARV drugs. This may reflect differences in the serological responses of those with ART-induced vs. natural viral suppression.

- Further research is needed to determine if these differences impact the performance of multi-assay algorithms for HIV incidence estimation.
Acknowledgments

• Coauthors: Ethan Klock, Oliver Laeyendecker, Estelle M. Piwowar-Manning, Ethan A. Wilson, William Clarke, Autumn Breaud, Ayana Moore, Helen Ayles, Peter Bock, Deborah Donnell, Sarah Fidler, Richard Hayes, Susan Eshleman, for the HPTN 071 (PopART) Study Team

• Overall support for the HIV Prevention Trials Network (HPTN) is provided by the National Institute of Allergy and Infectious Diseases (NIAID), Office of the Director (OD), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH) under Award Numbers UM1-AI068619-15 (HPTN Leadership and Operations Center), UM1-AI068617-15 (HPTN Statistical and Data Management Center), and UM1-AI068613-15 (HPTN Laboratory Center). Support was also provided by R01-AI095068 (Eshleman).

• The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.